Posted by Michael Wonder on 18 Jun 2020
Chi-Med announces fruquintinib granted U.S. FDA fast track designation for metastatic colorectal cancer
18 June 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted fast track designation for the development of fruquintinib for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy.
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor 1/2/3.
